By Stephen Nakrosis
Shares of Q32 Bio were touching all-time lows in the after-hours market following results from a pair of Phase 2a clinical trials of the company's alopecia treatment bempikibart.
The company said Tuesday that results from its Signal-AA trial demonstrated encouraging clinical activity of bempikibart in patients with alopecia areata, while the results from its Signal-AD trial in atopic dermatitis demonstrated promising findings in Part A but didn't meet primary endpoint in Part B.
After the bell, the company's shares had fallen 66%, to trade at $8.20. The stock touched an all-time low of $8.24 on Nov. 16, 2023.
Jason Campagna, the chief medical officer of Q32 Bio, said the company was looking forward to advancing bempikibart as a potential treatment for alopecia areata, which causes hair loss.
Chief Executive Jodie Morrison said Q32 plans to conduct a review to better understand the results of the Signal-AD trial.
Bempikibart was observed to be safe and well tolerated across both trials, the company said.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
December 10, 2024 18:32 ET (23:32 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。